Shaanxi Kanghui Pharmaceutical Co (SHSE:603139) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603139 Shaanxi Kanghui Pharmaceutical Co Ltd SHSE:603139
43 GF Score
Price ¥36.54
GF Value ¥14.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shaanxi Kanghui Pharmaceutical Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Shaanxi Kanghui Pharmaceutical Co Quality Rank Related Terms

SHSE:603139
43GF Score
Shaanxi Kanghui Pharmaceutical Co Ltd SHSE:603139
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shaanxi Kanghui Pharmaceutical Co (SHSE:603139) Overvalued in 2026?

Based on GuruFocus' analysis, Shaanxi Kanghui Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥36.54 is trading 147.6% above its estimated GF Value™ of ¥14.76. GuruFocus considers Shaanxi Kanghui Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:603139:

  • Quality Rank:
  • GF Value™: ¥14.76 vs. price of ¥36.54 (147.6% above fair value)
  • GF Score™: 43/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shaanxi Kanghui Pharmaceutical Co Business Description

Address No. 36, Yanzhi Road, Qindu District, Shaanxi Province, Xianyang, CHN, 71200
Shaanxi Kanghui Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company engaged in the research, development, production, and sale of both Western and traditional Chinese medicines. Its product portfolio includes tablets, capsules, granules, oral liquids, and liniments, with a focus on respiratory and cold remedies, gynecological treatments, and orthopedic and musculoskeletal medicines. Notable products include cold and cough formulations, anti-inflammatory and analgesic drugs, and women's health treatments. The company sells primarily to hospitals, clinics, pharmacies, and pharmaceutical distributors across China, with its main market in Shaanxi Province and other domestic regions. Revenue is generated mainly through the manufacture and sale of finished pharmaceutical products, supplemented by traditional Chinese medicine preparations. The company also invests in research and development to expand its drug pipeline and product approvals.
43GF Score

Get the complete analysis for SHSE:603139

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.54
Price
¥14.76
GF Value